SAN DIEGO / Nov 20, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, acadia.com , under the investors section and an archived recording will be available on the... Read More

Third quarter total revenues of $278.6 million, up 11% year-over-year Narrowing and raising high end of NUPLAZID ® net product sales guidance to $685 to $695 million Updating DAYBUE ® net product sales guidance to $385 to $400 million SAN DIEGO / Nov 05, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. “Acadia delivered... Read More

SAN DIEGO / Oct 28, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 10, 2025 at 2:00 p.m. Eastern Time in Palm Beach Gardens, FL Jefferies Global Healthcare Conference in London Presentation: Tuesday, November 18, 2025 at 8:30 a.m. Greenwich Mean Time in London Live... Read More

Company to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time SAN DIEGO / Oct 15, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 5,... Read More

SAN DIEGO / Oct 02, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson’s Disease and Movement Disorders ® being held October 5-9, 2025, in Honolulu, Hawaii. The presentations highlight updates from the company’s robust pipeline including preclinical efficacy,... Read More

SAN DIEGO / Sep 24, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). Intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from... Read More

Findings reinforce efficacy and tolerability profile in patients prescribed DAYBUE in the U.S. for as long as 12 months, consistent with the Phase 3 LAVENDER™ trial that supported FDA approval and open-label LILAC, LILAC-2 and DAFFODIL studies SAN DIEGO / Sep 12, 2025 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim... Read More

SAN DIEGO / Sep 08, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 161,676 shares of common stock and 49,363 restricted stock units (“RSUs”) to eighteen new employees under Acadia’s 2024 Inducement Plan. The... Read More

SAN DIEGO / Aug 26, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Monday, September 8, 2025 at 10:45 a.m. Eastern Time in New York, NY H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat: Tuesday, September 9, 2025 at 8:00 a.m. Eastern... Read More

SAN DIEGO / Aug 25, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia’s business development and corporate strategy and serve as a member of the Company’s Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of... Read More

SAN DIEGO / Aug 11, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 5, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 63,477 shares of common stock and 49,377 restricted stock units (“RSUs”) to twenty-six new employees under Acadia’s 2024 Inducement Plan. The... Read More

Second quarter total revenues of $264.6 million, up 9% year-over-year Second quarter NUPLAZID ® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year Second quarter DAYBUE ® (trofinetide) net product sales of $96.1 million, up 14% year-over-year Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance Top-line results expected for... Read More

SAN DIEGO / Aug 05, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45 th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be available on... Read More

Company to host conference call and webcast on Wednesday, August 6, 2025, at 4:30 p.m. Eastern Time SAN DIEGO / Jul 23, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 6, 2025, at 4:30... Read More

SAN DIEGO / Jul 03, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (“RSUs”) to seventeen new employees under Acadia’s 2024 Inducement Plan. The... Read More

SAN DIEGO / Jun 25, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during... Read More

SAN DIEGO / Jun 17, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (“RSUs”) to forty one new employees under Acadia’s 2024 Inducement Plan. The... Read More

Composition of matter patent affirmed, provides protection into 2030 Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO / Jun 09, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity... Read More

SAN DIEGO / Jun 05, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia’s management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community. To register for the live webcast, please... Read More

SAN DIEGO / May 29, 2025 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 4:00 p.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be... Read More

SAN DIEGO / May 27, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia’s commercial leadership team with a focus on maximizing the potential of DAYBUE ® and preparing for future product launches as the Company expands its rare disease portfolio. “We are... Read More

SAN DIEGO / May 20, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 7, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 64,252 shares of common stock and 56,277 restricted stock units (“RSUs”) to twenty-eight new employees under Acadia’s 2024 Inducement Plan. The... Read More

SAN DIEGO / May 16, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID ® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s order, the Court ruled in favor of Acadia on both infringement and validity arguments in its... Read More

First quarter total revenues of $244.3 million, up 19% year-over-year First quarter NUPLAZID ® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year First quarter DAYBUE ® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650... Read More

SAN DIEGO / May 05, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 3:40 p.m. Pacific Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be available on the... Read More

Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time SAN DIEGO / Apr 23, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m.... Read More

SAN DIEGO / Apr 11, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units (“RSUs”) to twenty-two new employees under Acadia’s 2024 Inducement Plan. The... Read More

SAN DIEGO / Mar 14, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units (“RSUs”) to thirteen new employees under Acadia’s 2024 Inducement Plan. The... Read More

SAN DIEGO / Mar 13, 2025 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat:... Read More

Study supported FDA and Health Canada approvals of DAYBUE for treatment of Rett syndrome in patients ages two years and older Results consistent with Phase 3 LAVENDER™ and open-label LILAC™ studies SAN DIEGO / Mar 05, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory... Read More

SAN DIEGO & COPENHAGEN, Denmark / Mar 03, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: 2024-514514-12-00) of ACP-711, formerly SAN711, in healthy volunteers. In the study, ACP-711 was safe and generally well tolerated across all dosing... Read More

SAN DIEGO / Feb 27, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 11:10 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be available on the... Read More

2024 total net product sales of $957.8 million, reflecting 32% revenue growth Fourth quarter DAYBUE ® (trofinetide) net product sales of $96.7 million and full year 2024 net product sales of $348.4 million Fourth quarter NUPLAZID ® (pimavanserin) net product sales of $162.9 million and full year 2024 net product sales of $609.4 million Full year 2025 total revenue guidance of $1.03 to $1.095 billion including DAYBUE net... Read More

SAN DIEGO / Feb 14, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 171,065 shares of common stock and 55,170 restricted stock units (“RSUs”) to eighteen new employees under Acadia’s 2024 Inducement Plan. The... Read More

Company to host conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. Eastern Time SAN DIEGO / Feb 12, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast... Read More

SAN DIEGO / Jan 17, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 13, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,782 shares of common stock and 13,928 restricted stock units (“RSUs”) to twelve new employees under Acadia’s 2024 Inducement Plan. The... Read More

SAN DIEGO / Jan 14, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2025 is shaping up to be an exciting year as we build... Read More

Filing marks company’s first Marketing Authorization Application in Europe SAN DIEGO / Jan 14, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing... Read More

SAN DIEGO / Dec 19, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of Acadia’s presentation will be... Read More

SAN DIEGO / Dec 16, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units (“RSUs”) to thirteen new employees under Acadia’s 2024 Inducement Plan. The... Read More

SAN DIEGO / Dec 11, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As described at the time the agreement to sell was announced on November 5, 2024, Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net proceeds, pursuant to a license... Read More

Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience SAN DIEGO / Dec 09, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its... Read More

SAN711 is a first-in-class, highly selective GABA A -α3 positive allosteric modulator Targeting initiation of Phase 2 study of SAN711 for the treatment of essential tremor in 2026 SAN DIEGO / Nov 26, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a... Read More

SAN DIEGO / Nov 21, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL Live... Read More

SAN DIEGO / Nov 15, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units (“RSUs”) to twenty-three new employees under Acadia’s 2024 Inducement Plan. The... Read More

3Q24 total revenues of $250.4 million, up 18% year-over-year 3Q24 NUPLAZID ® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year 3Q24 DAYBUE ™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year SAN DIEGO / Nov 06, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024. “The success of... Read More

SAN DIEGO / Nov 05, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE™ (trofinetide) for the... Read More

Company to host conference call and webcast on Wednesday, November 6, 2024, at 4:30 p.m. Eastern Time SAN DIEGO / Oct 17, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 6, 2024, at... Read More

DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO / Oct 16, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older under the Priority... Read More

SAN DIEGO / Oct 08, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 3, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,631 shares of common stock and 30,484 restricted stock units (“RSUs”) to thirteen new employees under Acadia’s 2024 Inducement Plan. The... Read More

SAN DIEGO / Sep 26, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 23, 2024, the Board of Directors granted Catherine Owen Adams, Acadia’s new Chief Executive Officer, a one-time sign-on equity award of (i) 353,261 options to purchase shares of Acadia’s common stock with an exercise price of $16.29 per share, Acadia’s closing trading price on September 23, 2024, which vest... Read More

Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers Squibb and Johnson & Johnson SAN DIEGO / Sep 23, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. “We are excited to welcome... Read More

SAN DIEGO / Aug 28, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Morgan Stanley 22 nd Annual Global Healthcare Conference Fireside Chat: Wednesday, September 4, 2024 at 4:50 p.m. Eastern Time in New York, NY Baird 2024 Global Healthcare Conference Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. Eastern Time in New... Read More

The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their family SAN DIEGO / Aug 14, 2024 / Business... Read More

SAN DIEGO / Aug 07, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at 10:00 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be... Read More

Second quarter total net product sales of $242.0 million, up 46% year-over-year SAN DIEGO / Aug 06, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024. “In the second quarter of 2024, Acadia delivered $242.0 million in net product sales, highlighted by 11% year-over-year growth in NUPLAZID net sales and 11% sequential growth in... Read More

Company to host conference call and webcast on Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time SAN DIEGO / Jul 24, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Tuesday, August 6, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 6, 2024, at 4:30... Read More

Continued Improvements in RSBQ and CGI-I scores seen with long-term DAYBUE treatment in Phase 3 LAVENDER™ and LILAC studies DAYBUE safety profile was consistent with findings from the LAVENDER trial SAN DIEGO / Jul 18, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from two open-label extension studies, LILAC-1™ and LILAC-2™, which showed that patients... Read More

SAN DIEGO / Jun 18, 2024 / Business Wire / Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with... Read More

SAN DIEGO / May 17, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units (“RSUs”) to twenty-two new employees under Acadia’s 2023 Inducement Plan. The... Read More

Video series created by Rett caregiver and award-winning TV producer, AJ Tesler, and family, showcases the adapted adventures of families living with Rett syndrome Documentary series to be showcased on Rett Revealed, a website designed to explain and highlight life with Rett syndrome SAN DIEGO / May 15, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of Magnolia’s Guide to... Read More

SAN DIEGO / May 09, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA... Read More

First quarter NUPLAZID ® (pimavanserin) net product sales of $129.9 million First quarter DAYBUE ™ (trofinetide) net product sales of $75.9 million SAN DIEGO / May 08, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024. “In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% revenue... Read More

10 academic scholarships awarded supporting siblings of Rett syndrome patients SAN DIEGO / Apr 29, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett... Read More

Company to host conference call and webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time SAN DIEGO / Apr 24, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m.... Read More

SAN DIEGO / Apr 22, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently... Read More

SAN DIEGO / Apr 19, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units (“RSUs”) to six new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Apr 17, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO. The presentations include outcomes from the DAFFODIL™, a Phase 2/3 open-label study evaluating the safety, tolerability... Read More

SAN DIEGO / Apr 02, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia. “Liz is a preeminent drug... Read More

SAN DIEGO / Apr 01, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com , under the investors section and an... Read More

SAN DIEGO / Mar 15, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Mar 13, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be available on the... Read More

Study Did Not Meet Primary Endpoint SAN DIEGO / Mar 11, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on... Read More

SAN DIEGO / Feb 29, 2024 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44 th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com , under the investors section and an archived recording will be available on the website for... Read More

2023 total net product sales of $726.4 million, reflecting 40% revenue growth. Fourth quarter DAYBUE ™ (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million. Fourth quarter NUPLAZID ® (pimavanserin) net product sales of $143.9 million and full year 2023 net product sales of $549.2 million. SAN DIEGO / Feb 27, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD),... Read More

SAN DIEGO / Feb 21, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 15, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,823 shares of common stock and 34,087 restricted stock units (“RSUs”) to seventeen new employees under Acadia’s 2023 Inducement Plan. The... Read More

Company to host conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. Eastern Time SAN DIEGO / Feb 13, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on... Read More

SAN DIEGO / Jan 30, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team. Jennifer J. Rhodes is joining the company as Executive Vice President, Chief Legal Officer and Secretary, and Kimberly J. Manhard as Senior Vice President, Global Strategic Planning and Execution, both effective immediately. Following a transition period, Austin D. Kim, Executive... Read More

SAN DIEGO / Jan 19, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 9, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 39,169 shares of common stock and 13,895 restricted stock units (“RSUs”) to eleven new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Jan 18, 2024 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness. “Serge” as he was known to friends and colleagues, joined Acadia in 2015 and led Acadia’s Research and Development organization for more than seven years. He... Read More

SAN DIEGO / Dec 21, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived... Read More

SAN DIEGO / Dec 18, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 13, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 33,647 shares of common stock and 20,146 restricted stock units (“RSUs”) to eight new employees under Acadia’s 2023 Inducement Plan. The... Read More

This is the second patent ruling issued today from the Court in favor of Acadia SAN DIEGO / Dec 13, 2023 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID ® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease... Read More

Court ruled in favor of Acadia on all grounds SAN DIEGO / Dec 13, 2023 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has granted summary judgment to Acadia, confirming validity of the NUPLAZID ® (pimavanserin) '740 composition of matter patent. The court ruled in favor of Acadia on all grounds. The ruling came in Acadia’s litigation... Read More

SAN DIEGO / Nov 30, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). PWS is a rare, neurobehavioral genetic disorder that is estimated to affect 8,000 to 10,000 patients in the United States. 1-4 The most common... Read More

SAN DIEGO / Nov 27, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Of the more than 6.5 million people in the United States living with Alzheimer’s disease (AD), approximately 30% will experience psychosis,... Read More

SAN DIEGO / Nov 21, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transitional period. The company has initiated a search for his replacement. About Acadia... Read More

SAN DIEGO / Nov 14, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 3, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 10,481 shares of common stock and 6,275 restricted stock units (“RSUs”) to nine new employees under Acadia’s 2023 Inducement Plan. The... Read More

Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise 3Q23 DAYBUE ™ (trofinetide) net product sales of $66.9 million 3Q23 NUPLAZID ® (pimavanserin) net product sales of $144.8 million SAN DIEGO / Nov 02, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023. “In the third quarter,... Read More

SAN DIEGO / Oct 31, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the Guggenheim Securities 5th Annual Inflammation & Immunology (I&I) Conference on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be... Read More

Company creates 10 academic scholarships supporting siblings in Rett syndrome community pursuing dreams in higher education Applications now available through January 31, 2024, for the 2024-2025 academic year SAN DIEGO / Oct 23, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the establishment of the Rett Sibling Scholarship, sponsored by Acadia to shine a light on the impact of Rett... Read More

Company to host conference call and webcast on Thursday, November 2, 2023, at 4:30 p.m. Eastern Time SAN DIEGO / Oct 19, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 2, 2023, at... Read More

SAN DIEGO / Oct 18, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 4, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 145,119 shares of common stock and 38,559 restricted stock units (“RSUs”) to 19 new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Sep 22, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 8, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,749 shares of common stock and 14,306 restricted stock units (“RSUs”) to 14 new employees under Acadia’s 2023 Inducement Plan. The... Read More

SAN DIEGO / Sep 19, 2023 / Business Wire / Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’s Executive Management Committee. He will report to Mark Schneyer, Executive Vice... Read More

SAN DIEGO / Aug 30, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 18 th Annual BioPharma Conference Date: Wednesday, September 6, 2023 Location: Boston, MA Format: 1x1 Meetings Morgan Stanley 21 st Annual Global Healthcare Conference Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time Location:... Read More

SAN DIEGO / Aug 14, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 1, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 40,612 shares of common stock and 14,990 restricted stock units (“RSUs”) to 16 new employees under Acadia’s 2023 Inducement Plan. The Compensation... Read More

2Q23 DAYBUE ™ (trofinetide) net product sales of $23.2 million 2Q23 NUPLAZID ® (pimavanserin) net product sales of $142.0 million Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO / Aug 02, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2023. “Our second quarter 2023 results reflect strong... Read More

SAN DIEGO / Aug 01, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 18, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 19,903 shares of common stock and 11,988 restricted stock units (“RSUs”) to 16 new employees under Acadia’s 2023 Inducement Plan. The Compensation... Read More

SAN DIEGO / Jul 24, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023. Dr. Oliver will oversee all business development functions and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, President and Chief Executive Officer of Acadia.... Read More

Company to host conference call and webcast on Wednesday, August 2, 2023, at 4:30 p.m. Eastern Time SAN DIEGO / Jul 19, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 2, 2023, at 4:30... Read More

Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first and only drug approved for the treatment of Rett syndrome Acadia provides DAYBUE launch update and announces second quarter preliminary net sales and guidance for third quarter Company to host conference call and webcast today at 4:30 p.m. Eastern Time SAN DIEGO / Jul 13, 2023 / Business Wire / Acadia Pharmaceuticals Inc.... Read More

SAN DIEGO / Jun 26, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 13, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 153,615 shares of common stock and 56,399 restricted stock units (“RSUs”) to 28 new employees under Acadia’s 2023 Inducement Plan. The Compensation... Read More

Acadia acquired Levo Therapeutics and worldwide rights to ACP-101 in June 2022 ACP-101 (intranasal carbetocin) is a selective oxytocin-receptor agonist for the treatment of hyperphagia in Prader-Willi syndrome Company recently completed a meeting with the FDA and plans to initiate a Phase 3 study in the fourth quarter of 2023 Webcast to be held today at 5:00 p.m. Eastern Time SAN DIEGO / Jun 13, 2023 / Business Wire / Acadia... Read More

Statistically significant differences demonstrated between DAYBUE ™ and placebo on efficacy endpoints relevant to Rett syndrome suggest treatment potentially capable of modifying core symptoms consistent with underlying pathophysiology of disease Study results provided basis for first FDA-approved treatment for Rett syndrome SAN DIEGO / Jun 08, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced... Read More

SAN DIEGO / Jun 01, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Eastern Time in New York, NY. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be available on the website for... Read More

1Q23 NUPLAZID ® net sales of $118.5 million Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 Announced DAYBUE Availability on April 17, 2023 SAN DIEGO / May 08, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2023.... Read More

SAN DIEGO / May 05, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (“RSUs”) to 44 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee of... Read More

SAN DIEGO / May 02, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: BofA Securities 2023 Health Care Conference Fireside Chat: Wednesday, May 10, 2023 at 2:20 p.m. Eastern Time in Las Vegas, NV The JMP Securities Life Sciences Conference Fireside Chat: Tuesday, May 16, 2023 at 2:30 p.m. Eastern Time in New York, NY 2023... Read More

Company to host conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. Eastern Time SAN DIEGO / Apr 25, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Monday, May 8, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2023, at 4:30 p.m. Eastern... Read More

SAN DIEGO / Apr 20, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Mass. The poster presentations include a secondary analysis reporting on the communication-related endpoints from the pivotal Phase 3 LAVENDER™ study and an... Read More

Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S. 1 SAN DIEGO / Apr 17, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that DAYBUE ™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years... Read More

SAN DIEGO / Apr 11, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22 nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time. The conference will be held virtually. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording... Read More

SAN DIEGO / Mar 10, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE ™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome. "Today marks an important milestone for the Rett community and... Read More

SAN DIEGO / Feb 27, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2022. NUPLAZID ® delivered net sales of $136.5 million in the fourth quarter of 2022 and $517.2 million for the full year. The improvement was mainly driven by an increase in demand in the long-term care channel and retention of continuing... Read More

SAN DIEGO / Feb 14, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 27, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference... Read More

SAN DIEGO / Feb 13, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 10, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 310,065 shares of common stock and 97,251 restricted stock units (“RSUs”) to 19 new employees under Acadia’s 2023 Inducement Plan. Among such awards was a... Read More

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr. Srdjan Stankovic, whose planned... Read More

Study results consistent across different patient groups, including those in long-term care facilities Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID ® (pimavanserin) compared to other atypical antipsychotics over 12 months and... Read More

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be available on the website for... Read More